265 related articles for article (PubMed ID: 19563648)
21. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
Hafiz AM; Jan MF; Mori N; Shaikh F; Wallach J; Bajwa T; Allaqaband S
Catheter Cardiovasc Interv; 2012 May; 79(6):929-37. PubMed ID: 21542114
[TBL] [Abstract][Full Text] [Related]
22. [Prevention of contrast-induced nephropathy using cardiac catheterization combined with hydration, oral N-acetylcysteine, sodium bicarbonate and iso-osmolar contrast agents].
Hoshino A; Enomoto S; Kawahito H; Kurata H; Nakahara Y; Nakamura T
J Cardiol; 2007 Aug; 50(2):119-26. PubMed ID: 17802695
[TBL] [Abstract][Full Text] [Related]
23. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial.
Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D
Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
25. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
26. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial.
Carbonell N; Blasco M; Sanjuán R; Pérez-Sancho E; Sanchis J; Insa L; Bodí V; Núñez J; García-Ramón R; Miguel A
Int J Cardiol; 2007 Jan; 115(1):57-62. PubMed ID: 16814414
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
Seyon RA; Jensen LA; Ferguson IA; Williams RG
Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
[TBL] [Abstract][Full Text] [Related]
28. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
[TBL] [Abstract][Full Text] [Related]
29. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
31. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
[TBL] [Abstract][Full Text] [Related]
33. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
34. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography.
Calabrò P; Bianchi R; Crisci M; Caprile M; Bigazzi MC; Palmieri R; Golia E; De Vita A; Romano IJ; Limongelli G; Russo MG; Calabrò R
Intern Emerg Med; 2011 Dec; 6(6):503-7. PubMed ID: 21279477
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography.
Durham JD; Caputo C; Dokko J; Zaharakis T; Pahlavan M; Keltz J; Dutka P; Marzo K; Maesaka JK; Fishbane S
Kidney Int; 2002 Dec; 62(6):2202-7. PubMed ID: 12427146
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.
Reinecke H; Fobker M; Wellmann J; Becke B; Fleiter J; Heitmeyer C; Breithardt G; Hense HW; Schaefer RM
Clin Res Cardiol; 2007 Mar; 96(3):130-9. PubMed ID: 17180572
[TBL] [Abstract][Full Text] [Related]
37. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
38. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
[TBL] [Abstract][Full Text] [Related]
39. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
[TBL] [Abstract][Full Text] [Related]
40. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
Miner SE; Dzavik V; Nguyen-Ho P; Richardson R; Mitchell J; Atchison D; Seidelin P; Daly P; Ross J; McLaughlin PR; Ing D; Lewycky P; Barolet A; Schwartz L
Am Heart J; 2004 Oct; 148(4):690-5. PubMed ID: 15459602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
